MAPT and Alzheimer disease: Together, since metformin use has been shown to reduce Aβ deposition and abnormal tau phosphorylation, alleviate inflammation, moderate insulin-sensitizing, and enhance the neurogenesis [393, 394], all of which are key mechanisms for AD, the relationship between metformin use and AD risk warrants further investigation.